Beijing Continent Pharmaceutical Co, Ltd.

This study tests a drug called hydronidone in people with liver scarring (fibrosis) from chronic hepatitis B. About 1,200 adults will take either hydronidone or a placebo, along with standard antiviral therapy, for up to 5 years. The goal is to see if hydronidone can prevent seri…

This early-stage study tests hydronidone capsules in 138 healthy Chinese adults to see how the body absorbs, breaks down, and eliminates the drug. It also checks for side effects. The goal is to gather safety and dosing information for future studies on liver fibrosis, not to tre…

This early-stage study looks at how a new drug for liver scarring (hydronidone) interacts with four standard hepatitis B antivirals. It involves 64 healthy adults aged 18 to 50. The goal is to check for any drug interactions and help doctors prescribe these medicines together saf…

This study looks at how the drug Hydronidone is absorbed, broken down, and removed from the body. Eight healthy Chinese men will take a single dose with a radioactive marker so researchers can track it in blood, urine, and stool. The goal is to understand the drug's behavior, not…

This study looks at how a single dose of hydronidone moves through the body in 30 adults with different levels of liver function, from normal to severely impaired. Researchers want to see if liver problems change how the drug is processed, which can help doctors choose the right …